GlassScriptPhysician profile
Stuart L Willson
NPI 1841262045
$6,725.42
in general payments reported to CMS, 2019-2025
36 companies · $65.44 in 2025
The $65.44 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $564 · 2020: $654 · 2021: $1,703 · 2022: $1,769 · 2023: $1,661 · 2024: $310 · 2025: $65.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,036.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,035.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,128.92 | 2019-2023 | Trulicity, Mounjaro, Humulin |
| Novo Nordisk INC | $1,046.04 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $487.34 | 2019-2023 | Repatha, Otezla, Enbrel |
| Bayer Healthcare Pharmaceuticals INC. | $472.15 | 2021-2023 | |
| Abbvie INC. | $421.63 | 2020-2022 | |
| Xeris Pharmaceuticals, INC. | $321.62 | 2020-2023 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $317.89 | 2019-2023 | Arexvy, Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $303.41 | 2021-2023 | Jardiance |
| Mannkind Corporation | $290.30 | 2019-2023 | Afrezza |
| Mallinckrodt Hospital Products INC. | $180.66 | 2021-2022 | |
| Amarin Pharma, INC. | $175.77 | 2020-2022 | |
| Cvrx, INC. | $169.05 | 2024 | Barostim Neo System |
| Insulet Corporation | $154.97 | 2022-2024 | Omnipod |
| Dexcom, INC. | $150.75 | 2021-2023 | Dexcom G6 Transmitter |
| Alexion Pharmaceuticals, INC. | $100.00 | 2022-2024 | Strensiq |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alvogen INC | $98.12 | 2022-2023 | Teriparatide |
| Mallinckrodt Enterprises LLC | $90.89 | 2019 | |
| Abbott Laboratories | $87.94 | 2019-2023 | Freestyle Libre 3 |
| Corcept Therapeutics | $76.08 | 2019-2023 | Korlym |
| Radius Health, INC. | $75.28 | 2021-2023 | Tymlos |
| Pfizer INC. | $71.34 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $59.27 | 2020-2023 | |
| Ibsa Pharma INC. | $58.60 | 2022-2023 | Tirosint, Licart |
| Merck Sharp & Dohme LLC | $48.52 | 2019-2022 | |
| Janssen Biotech, INC. | $47.90 | 2022 | |
| Esperion Therapeutics, INC. | $47.90 | 2021 | |
| Ascensia Diabetes Care US INC. | $36.63 | 2021 | |
| Exact Sciences Corporation | $35.73 | 2023 | Cologuard Collection Kit |
| Becton, Dickinson and Company | $28.00 | 2021 | |
| Fresenius Kabi USA, LLC | $26.60 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $25.50 | 2023 | Nuedexta |
| Sanofi-Aventis U.S. LLC | $20.40 | 2019 | |
| Kyowa Kirin, INC. | $18.18 | 2023 | |
| Ascend Therapeutics US, LLC | $18.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.25 | 2021 | |
| Tandem Diabetes Care, INC. | $16.79 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Willson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.